ArticleBMC bioinformatics2026
Transcriptome graph transformer: a graph transformer-based unsupervised model for transcriptome data analysis.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-modality Graph Representation Learning for Malignant Cell Identification from scRNA-seq using DeepMalignant.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRapidly growing transcriptomic datasets pose challenges for traditional analytical methods, which struggle with high dimensionality, heterogeneity, and nonlinear gene relationships. Existing deep learning models often require fixed-length inputs and fail to integrate biological network information.
methodsWe introduce Transcriptome Graph Transformer (TGT), an unsupervised graph Transformer framework that constructs a heterogeneous gene-pathway graph using expression data, STRING interactions, and GO/KEGG/Reactome pathway annotations. TGT is pretrained with a masked-node prediction task and fine-tuned for disease classification, biomarker discovery, and zero-shot clustering of single-cell and spatial transcriptomics.
resultsTGT achieves superior performance across Alzheimer's disease, cancer, acute kidney injury, and COVID-19 datasets, outperforming state-of-the-art baselines. The model generalizes well across platforms and yields biologically meaningful gene and pathway importance scores consistent with known disease mechanisms.
conclusionsTGT provides an effective and generalizable approach for transcriptomic representation learning by integrating biological network knowledge with graph Transformer architectures. Its strong performance highlights its utility for broad transcriptomic applications and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.